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Abstract
Background: Anterior gradient 2 (AGR2) is a protein disulfide isomerase-like protein widely expressed in many
normal tissues as well as cancers. In our study, non-neoplastic bronchial epithelial cells as well as non-small cell
lung cancer (NSCLC) cells express AGR2 protein.
Methods: AGR2 expression was analyzed on lung tissue microarrays. Tumor staining was correlated with clinical
outcomes.
Results: On a lung cancer tissue microarray using immunohistochemistry, expression levels in cancer showed
generally decreasing intensities in order from adenocarcinomas with mucinous components, other adenocarcinomas,
squamous carcinomas, to large cell carcinomas. The study cohort was comprised of 400 cases.
As a group, there was a slight trend of lower expression with increasing tumor grade. AGR2 expression level was a
significant predictor of overall survival in younger patients only. Patients under 65 with lower levels showed a
significantly better survival for both men and women. Patients over 65, in contrast, showed no such trend.
Conclusions: Nearly all NSCLC tumors show AGR2 expression. Lung cancer expression of AGR2 has prognostic value
for younger patients.
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Background
Lung cancer is the leading cause of cancer related deaths
in the United States and many parts of the world. Ac-
cording to the American Cancer Society approximately
224,210 individuals in the United States will be diag-
nosed with the disease and 159,260 (71 %) will die of it
in 2014 [1]. Most of these are classified as non-small cell
lung cancers (NSCLC), and include adenocarcinomas,
squamous carcinomas, large cell carcinomas as well as
less commonly occurring histopathologic patterns such
as adenosquamous carcinoma. The search continues for
bio-markers which can delineate outcomes related to
long term survival or response to treatments.
Anterior gradient 2 (AGR2) is expressed by many solid
tumor types and is known as an adenocarcinoma antigen
[2]. In prostate cancer, expression of AGR2 is increased
in the tumor epithelial cells; normal luminal cells have
no detectable expression [3, 4]. In bladder cancer,
expression of AGR2 is absent in ~75 % cases; normal
urothelial cells have moderate AGR2 expression (in
comparison to that in prostate cancer cells) [5]. Expres-
sion in primary prostate cancer is associated with lower
grade disease (and longer biochemical recurrence-free
survival) [6, 7]. Breast cancer also shows AGR2 expres-
sion [8]. Like prostate cancer, high AGR2 expression is
associated with low grade and low expression with high
grade. Besides differential expression in tumor grades,
AGR2 expression is found preferentially in the adenocar-
cinoma type than the squamous cell carcinoma type of
NSCLC [9]. In esophageal cancer, AGR2 can be used to
improve distinguishing adenocarcinoma (99 % positive)
from squamous cell carcinoma (37 % positive, typically
in focal areas) in some circumstances [10]. However, oral
squamous cell carcinoma has recently been reported to
express AGR2 [11].
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From the foregoing description, it would appear that
cancer expression of AGR2 is more associated with dis-
eases that have a lower potential of progression. This
contrasts with the molecular functioning of AGR2 in
cancer cells. Cell lines transfected with AGR2 produced
metastasis in a xenograft model [12], showed gain of
anchorage-independent growth and promoted tumor
growth [13]. In gastric cancer cells, AGR2 expression
was found up-regulated in a cancer cell subline with
high metastatic potential for invasion to lymph nodes
[14]. Although AGR2 positive primary prostate tumors
were associated with better clinical outcome than AGR2
negative tumors, many distal prostate cancer metastases
in bone and visceral organs showed strong immuno-
staining for AGR2 [7]. In ovarian cancer, high AGR2
expression was reported in 12 % high-grade serous type,
which showed significantly lower overall survival [15].
Thus, AGR2 has a prognostic value for some cancers,
but this is variable.
The widespread expression of AGR2 in human cancer
underscores its potential importance in tumor biology.
In some organs like the prostate and pancreas, AGR2 is
absent in normal epithelial cells and present in cancer
cells, while in others like the bladder, AGR2 is present in
normal urothelial cells but absent in cancer cells of a
majority of tumors. AGR2 expression being a feature of
low grade cancer appears to contradict the metastasis
promoting property of AGR2. This may be due more to
our lack of understanding about the precise molecular
functioning of AGR2 in cancer. In this paper, we de-
scribe AGR2 expression in NSCLC and adjacent non-
neoplastic lung tissue. We also show it has prognostic
value in younger NSCLC patients.
Methods
Ethics statement
This research was approved by the UCLA Office of
Human Research Protection Program (IRB 11–00–1301)
and the UW-Fred Hutchinson Cancer Research Center
Institutional Review Board (Protocol 9147). For use of
pre-constructed lung tissue microarrays (TMA) at
UCLA, this study did not meet the definition of human
subjects research, so no patient signatures were obtained
again as they were not required. No children participants
were enrolled.
Lung tissue microarrays
The lung TMA was constructed with archival formalin-
fixed, paraffin embedded lung tissue samples and has
previously been described in detail [16, 17]. Tissues sam-
pled included primary lung tumor, as well as adjacent
non-neoplastic lung parenchyma and metastatic lung
carcinoma to lymph nodes and distant sites. All tumors
were reviewed by at least two pathologists to confirm
the diagnoses. At least three core tissue biopsies,
0.6 mm in diameter, were taken from morphologically
representative regions for all histologies sampled and
precisely arrayed using a custom built instrument as
described before [16]. The TMA contained 1,202 in-
formative tissue cores of NSCLC types and 132 cores of
non-neoplastic bronchial/bronchiolar tissue from a
cohort of 400 patients. The NSCLC types included
adenocarcinoma, squamous carcinoma and large cell
carcinoma as well as smaller numbers of neuroendocrine
(carcinoid and atypical carcinoid) and adenosquamous
carcinomas. A detail of the patient demographics is
shown in Table 1.
TMA immunohistochemistry
The lung TMA was stained using a standard two-step
indirect immunohistochemistry similar to previous
experiments described [6]. Briefly, tissue sections were
cut immediately prior to being stained, deparaffinized in
xylene, and rehydrated in graded ethanol solutions.
Endogenous peroxidase was quenched with 3 % hydrogen
Table 1 Patient demographics and AGR2 expression by
subgroups
AGR2 expression (integrated mean intensity) by subgroups
Group n (mean ± SEM) P-value
Gender 0.025b
Women 205 1.33 ± 0.04
Men 194 1.18 ± 0.04
Stage 0.202a
Stage I 224 1.29 ± 0.04
Stage II 70 1.16 ± 0.07
Stage III 77 1.30 ± 0.07
Stage IV 27 1.09 ± 0.09
Grade 0.004a
Grade 1 63 1.34 ± 0.08
Grade 2 112 1.33 ± 0.06
Grade 3 158 1.26 ± 0.05
Grade 4 35 0.94 ± 0.07
Histology 1.07e-11a
Adenocarcinoma 233 1.43 ± 0.04
Adenosquamous carcinoma 19 1.36 ± 0.14
Squamous cell carcinoma 104 1.00 ± 0.05
Undifferentiated carcinoma 33 0.96 ± 0.07
Smoking status 3.50e-04a
Non-smokers 52 1.55 ± 0.09
Former smokers 158 1.27 ± 0.04
Current smokers 128 1.12 ± 0.05
aKruskal-Wallis test
bMann-Whitney U test
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peroxide. The sections were placed in a 95 °C solution
of 0.01 M sodium citrate buffer pH 6.0 for antigen
retrieval.
AGR2 expression was evaluated on the TMA with
NB110-17780 rabbit polyclonal (Novus Biologicals) at
2 μg/ml concentration as described [6]. Specific staining
was detected by applying anti-rabbit horseradish
peroxidase-conjugated secondary antibody and Vector
ABC (Vector Laboratories, Burlingame, CA). As negative
control, staining was performed with concentration-matched
non-immune IgG. This antibody was used extensively in
our prostate and bladder cancer immunostaining study
with good performance.
Semiquantitative assessment of staining was per-
formed by a pathologist (MA) without prior knowledge
of clinical information. A number value was calculated
based on staining intensity (0 = not detectable, 1 = weak,
2 = moderate, 3 = strong) and percentage of cells staining
at each intensity level (0–100 %). A final integrated value
of intensity and frequency was determined using the
formula: [(3x) + (2y) + (1z)]/100, where x, y, and z were
the percent staining at intensity levels 3, 2, and 1, respect-
ively. For outcomes analysis based on tumor expression of
the marker, a pooled value for each patient was deter-
mined by taking the mean expression across cores with
the appropriate tumor histology. We have used this study
methodology previously [6, 7, 16–25].
Statistical analysis
Lung cancer AGR2 expression was examined for correla-
tions with tumor characteristics and overall survival.
Briefly, the non-parametric Mann–Whitney and Kruskal-
Wallis tests were used for two-group and multi-group
comparisons. Correlations of continuous or ordered vari-
ables were calculated using Spearman Correlation. Patients
were dichotomized at the median level of AGR2 expres-
sion for survival differences and visualization was by
Kaplan-Meier plots. The Cox proportional hazards model
was used to test the statistical significance of predictors in
both a univariate and a multivariate setting. Logrank
P values were used and P < 0.05 was considered signifi-
cant. All statistical analyses were performed with the freely
available R software (https://www.r-project.org/).
Results
Expression patterns of AGR2
Higher levels of AGR2 expression were seen in non-
neoplastic bronchial epithelium compared to NSCLC
cells. This is illustrated in Fig. 1, which shows compari-
sons at the individual tissue core level. For cancer cells,
adenocarcinomas displayed slightly stronger staining on
average than squamous or large cell carcinomas. Of the
400 patient cases, only 7 had tumors with no staining
comprising 1 % of adenocarcinoma, 4 % of squamous
carcinoma, and 4 % of large cell carcinoma. Although in
all NSCLC, AGR2 expression appeared to be inversely
correlated to grade (P = 0.004), the major contributor
was the lower expression in grade 4 tumors (large cell
carcinomas). When examining adenocarcinomas and
squamous carcinomas separately the grade correlation
was absent (Fig. 2). No significant differences were seen
in tissue staining in primary sites, lymph node metasta-
ses and distant metastases (Fig. 3). Examples of cell
staining are shown in Fig. 4. AGR2 was predominantly
localized to the cytoplasm, although occasionally there
was sparse and faint nuclear staining.
Tumor AGR2 expression was arbitrarily sorted into
high with integrated intensity >1, and low with inte-
grated intensity ≤1. Tables 2 and 3 shows the per-
centages of high and low AGR2 expressors among the
Fig. 1 AGR2 staining intensity of lung tissue. Staining is scored by integrated intensity values on the vertical axis for the tissue types listed on the
horizontal axis. Normal bronchial epithelium shows the strongest staining for AGR2. The number of tissue examples scored is indicated by n
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different grades. For all tumor cores, the high AGR2
fractions were 59 % for grade 1, 48 % for grade 2, 43 %
for grade 3, and 22 % for grade 4. This reflected the
overall decrease in AGR2 staining with increasing grade.
When segregated by tumor types, high AGR2 expression
was more pronounced in adenocarcinoma: 62 % for
Fig. 2 AGR2 expression and tumor grade. The box plots show a decrease in integrated intensity values with increasing tumor grades (top panel).
This correlation was not evident when separated by tumor types (middle panel for adenocarcinoma; bottom panel for squamous carcinoma).
Adenocarcinoma grade 3 shows low staining intensity but squamous carcinoma shows higher staining intensity
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Fig. 3 AGR2 expression in primary vs. metastatic sites. No significant differences in AGR2 expression was seen in primary, lymph node metastasis,
and distant metastasis. This applied to adenocarcinomas, squamous carcinomas and large cell carcinomas
Fig. 4 AGR2 immunostaining of lung epithelial cells. Shown are examples of lung epithelial cells stained for AGR2: a, normal bronchiolar epithelium;
b, bronchioloalveolar carcinoma, mucinous type; c, moderately differentiated adenocarcinoma; d, moderately differentiated squamous carcinoma;
e, poorly differentiated adenocarcinoma; f, large cell carcinoma
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grade 1, 62 % for grade 2, and 51 % for grade 3; whereas
in squamous carcinoma: 19 % for grade 1, 20 % for grade
2, and 31 % for grade 3. Comparisons with other clinical
variables were also examined. Interestingly, there were
differences in expression by smoking status. Non-
smokers had the highest levels, followed by former
smokers and current smokers (P = 3.5E-04, Fig. 5).
Current smokers included those smoking at the time of
diagnosis as well as those who had quit within a year.
Overall expression was slightly higher in women than
men (P = 0.025). There was no correlation between stage
and AGR2 expression (P = 0.21, ρ = −0.06). A summary
of the findings is shown in Table 1.
Tumor AGR2 expression and overall patient survival
The entire cohort was examined at first for correlation
between AGR2 and overall survival. AGR2 as a predictor
did not quite reach significance, with the univariate Cox
proportional hazards model P = 0.077 and hazard ratio
(HR) = 1.2. The population was then divided by gender,
age, smoking status and histology. With the univariate
Cox proportional hazards model, AGR2 was a significant
predictor for survival in younger patients, those under
age 65 (P = 0.007, HR = 1.73). For a Kaplan-Meier plot,
the median expression value was chosen as a non-biased
cut point for dichotomizing the population. Higher
levels were associated with poorer survival with P = 0.01
and HR = 2.00 (Fig. 6). When examining men and
women in the younger age group separately, AGR2 was
predictive for survival in both groups. In a multivariate
model with stage, grade, age and AGR2 staining intensity
(Table 4), AGR2 was an independent predictor of
survival in patients under 65 (P = 0.002). However,
this trend was not observed in patients over age 65
(P = 0.964, HR = 0.993). When dividing all patients by
stage only, AGR2 as a continuous variable was predictive
for survival in stage I [P = 0.047, hazard ratio (HR) = 1.50]
but not higher stages: stage II (P = 0.13, HR = 1.50); stage
III (P = 0.25, HR = 1.30); stage IV (P = 0.61, HR = 1.33).
When examining younger patients with stage I, although
hazard ratio was slightly higher (HR = 1.85, the P-value
did not reach significance because of the smaller size of
the patient group. AGR2 did not predict survival dif-
ferences when patients were divided by histology
(adenocarcinoma vs. squamous carcinoma) or by smoking
status.
Discussion
AGR2 is classified as a member of the protein disulfide
isomerase (PDI) family of proteins on the basis of amino
acid sequence homology. It is localized to the endoplas-
mic reticulum (ER) as well as secreted [3]. It has also
been found in the nucleus and on the cell surface. PDI
enzymes contain CXXC domains, which function in oxi-
dation/reduction reactions and isomerization of disulfide
bridges. Several PDI family members including AGR2
contain a CXXS motif, and exhibit a lower enzymatic
activity than those with CXXC domains [2]. In normal
tissues, AGR2 is strongly expressed in lung, trachea, GI
tract, and tissues that contain mucin secreting cells or
have endocrine functions [2]. Like the bladder urothe-
lium, AGR2 is expressed in the normal bronchial epithe-
lium. Unlike urothelial carcinoma cells, where AGR2
expression is frequently absent, the lung cancer cells re-
tain AGR2. Like prostate, pancreatic, and breast cancer,
tumor expression decreases somewhat with increasing
grade. With this common trend, we expected cancer ex-
pression of AGR2 to be correlated with better patient
survival as was demonstrated for prostate cancer [6].
However, this was not the case for lung cancer, in
particular, for patients younger than 65. Instead, like
high-grade serous ovarian cancer, higher cancer AGR2
expression is correlated with poorer survival. A possible
explanation is that AGR2 functions differently in the
cancer cell types, or that other differentially expressed
genes affect AGR2 function. Depending on the cancer
cell types, AGR2 may play roles in differentiation (as in
low grade prostate tumors), cell growth and migration
(as in advanced prostate cancer) [13].
AGR2 transcription is reported to be regulated by both
estrogen and androgen receptors. Upregulation of AGR2
was seen in response to estradiol [26]. AGR2 was identi-
fied as being differentially expressed in estrogen receptor
(ERα) positive breast cancer cell lines. Treatment of breast
Table 2 High vs. low tumor AGR2 expression. The percentages
of tissue cores showing low vs. high integrated intensity values for
the different tumor grades in adenocarcinoma and squamous
carcinoma are tabulated
All tissue cores
Grade 0 G1 G2 G3 G4
Low AGR2 (%) 24 41 52 57 78
High AGR2 (%) 76 59 48 43 22
Table 3 High vs. low tumor AGR2 expression. The percentages
of tissue cores showing low vs. high integrated intensity values
for the different tumor grades in adenocarcinoma and
squamous carcinoma are tabulated
Adenocarcinoma
Grade G1 G2 G3
Low AGR2 (%) 38 38 49
High AGR2 (%) 62 62 51
Squamous carcinoma
Grade G1 G2 G3
Low AGR2 (%) 81 80 69
High AGR2 (%) 19 20 31
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cancer patients with Letrazole resulted in decreased
AGR2 transcription [26]. Interestingly, tamoxifen en-
hanced AGR2 expression [27], and AGR2 was found to be
a predictor of poorer prognosis in tamoxifen-treated
breast cancers [28]. Binding sites for FOXA1, FOXA2,
hepatic nuclear factor 1, NF-κB and SOX9 were identified
in the promoter region of AGR2 [26]. MAPK/ERK signal-
ing was shown to regulate AGR2 expression in tumor cell
lines in response to physiological stress from serum and
oxygen depletion [29]. Vanderlaag et al. showed AGR2
could regulate cell growth, cell cycle progression, and
survival in breast cancer cells through modulation of
cyclin D1, ERα and survivin [30]. In addition, AGR2 can
negatively regulate the p53 transcriptional pathway [31].
Dong et al. reported that binding of EGFR to AGR2 in the
ER was necessary for transport of EGFR to the cell surface
for EGFR signaling [32]. Huang et al. suggested various
proteins and pathways influenced by AGR2 that may
affect tumor metastasis including MAST1, SOAT2,
POU2AF1 and IFI6 [33]. These studies demonstrate
the multi-faceted functional aspect of this protein.
Therefore, depending on the precise interaction in
particular cell types AGR2 can have different effects on
Fig. 5 AGR2 expression and smoking status. Non-smokers had on average slightly higher levels than smokers
Fig. 6 Kaplan-Meier survival plot for AGR2 expression levels. For
patients under 65, high tumor AGR2 expression is correlated with a
poorer survival than low tumor AGR2 expression
Table 4 Multivariate cox model for younger patients including
AGR2, tumor stage, grade and patient age
Multivariate cox model for patients under age 65
Variable Hazard ratio (95 % confidence interval) P-value
AGR2 1.86 (1.25 -2.76) 0.002
Stage 1.70 (1.32 -2.20) 3.89E-05
Grade 1.56 (1.10 -2.23) 0.013
Age 1.005 (0.97- 1.04) 0.796
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tumor cell behavior. Further studies on the molecular
biology of AGR2 in cancer as well as normal cell types
are needed.
Our study results differed in some aspects with those
in the literature. In studying AGR2 in lung cancers,
Fritzsche et al. [9] found no association of AGR2 expres-
sion and survival in 95 cases of NSCLC. Their conclu-
sion was based on a smaller number of patients without
the cohort dichotomization along age 65. When we con-
sidered our entire NSCLC population, we also did not
find a significant predictive value for AGR2. The predict-
ive value became significant only when younger patients
were considered. Their paper, as well as that of Pizzi et
al. [34], reported stronger staining in adenocarcinomas
vs. squamous carcinomas, similar to our results. Inoue et
al. [35] reported AGR2 expression in almost all adeno-
carcinomas, 96 % squamous carcinomas and 3/3 large
cell carcinomas, as well as AGR2 RNA in positive lymph
nodes. This contrasts with the general lower expression
in squamous carcinomas and large cell carcinomas in
our series. Chung et al. [36] reported that AGR2 was
up-regulated almost 10-fold in lung adenocarcinoma,
and negative expression (seen in 6 % of cases) was
associated with poor survival. We did not observe AGR2
up-regulation in cancer cells vs. normal cells. Chung et
al. [37], however, also reported a significantly higher
mean serum AGR2 level even for stage I lung adenocar-
cinoma (AUC = 0.858), and positive serum AGR2 to
be associated with recurrence after surgery (P = 0.025)
and poor prognosis. Park et al. showed AGR2 to be
present within the ER of intestinal secretory epithelial
cells, to interact with MUC2 and to be a necessary
requirement for mucus production and protection
from colitis [38]. That adenocarcinomas with areas of
mucinous histologic patterns in our study had higher
AGR2 levels on average fits with a role for AGR2 in
mucin production.
AGR2 could potentially become a viable serum bio-
marker for lung cancer [37]. In healthy people, the
serum level of AGR2 is non-detectable or very low.
This was borne out by mass spectrometry proteomics
[39] and query of the PeptideAtlas database [40] that
showed very low AGR2 signature peptide counts re-
ported to date.
Conclusions
Normal lung epithelial cells express AGR2 and most
NSCLC cells retain this marker. For NSCLC in younger
patients, higher tumor AGR2 expression is correlated with
a poorer survival in our cohort. Although not as strong a
finding, patients with stage I cancer also showed poorer
survival with higher levels of AGR2, which could suggest a
deleterious role for AGR2 in lung cancer.
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